Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple combination therapies in chronic hepatitis B
NCT04225715Phase 2Completed
- Sponsor
- Roche
- Start
- Jul 2020
- Primary completion
- Jul 2024
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Conjugated siRNA
- Countries
- 13
01
Overview
Phase 2, randomised, open-label trial of xalnesiran, linvencorvir, ruzotolimod and cadapersen in Chronic Hepatitis B (CHB) (9 arms), sponsored by Roche. Primary endpoint: Hepatitis B Surface Antigen Loss. Started Jul 2020; status: completed.
02
Drugs
xalnesiranlinvencorvirruzotolimodcadapersen
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04225715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04225715.